Drug Trial Radar · NCT02626026
Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)
Last checked: Nov 20, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jan 26, 2016
Primary completion
Sep 1, 2016
Study completion Sep 1, 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Dec 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will consist of two parts: Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirabrutinib in healthy participants. Part B will evaluate the safety, tolerability, and the effect of tirabrutinib on disease-specific clinical markers and outcomes in participants with rheumatoid arthritis (RA).
Conditions
- Rheumatoid Arthritis
Interventions
TirabrutinibDrug
Capsules administered orally.
PlaceboDrug
Capsules administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days
- Part A: Percentage of Participants With Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to last dose (maximum: 7 days) plus 30 days
- Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) AbnormalitiesTime frame: First dose date up to last dose (maximum: 7 days) plus 30 days
- Part A: Cmax: Maximum Observed Plasma Concentration of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
- Part A: Clast: Last Observed Quantifiable Plasma Concentration of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
- Part A: Tmax: Time (Observed Time Point) of Cmax of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
- Part A: Tlast: Time (Observed Time Point) of Clast of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
- Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of TirabrutinibTime frame: Cohorts 1 and 2, Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose relative to the morning dose
- Part A: AUClast: AUC Versus Time Curve From Time Zero to the Last Quantifiable Concentration of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
- Part B: Percentage of Participants Who Experienced TEAEsTime frame: First dose date up to last dose (maximum: 29 days) plus 30 days
- Part B: Percentage of Participants With Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to last dose (maximum: 29 days) plus 30 days
- Part B: Percentage of Participants With 12-Lead ECG AbnormalitiesTime frame: First dose date up to last dose (maximum: 29 days) plus 30 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UC Davis Lawrence J. Ellison
Sacramento, California
SeaView Research, Inc.
Miami, Florida
Omega Research Consultants, LLC
Orlando, Florida
Lovelace Scientific Resources, Inc.
Venice, Florida
Center for Arthritis & Osteoporosis
Elizabethtown, Kentucky
Justus J. Fiechtner, M.D., P.C.
Lansing, Michigan
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Clinical Research Center of Reading, LLC
Wyomissing, Pennsylvania
Arthritis & Osteoporosis Center of South Texas
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.